Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly

Ph Caron, A. Beckers, D. R. Cullen, M. Góth, B. Gutt, P. Laurberg, A. M. Pico, M. Valimaki, W. Zgliczynski

Research output: Contribution to journalArticle

156 Citations (Scopus)

Abstract

Lanreotide Autogel is a new long-acting aqueous preparation of lanreotide for the treatment of acromegaly and is administered by deep sc injection from a small volume, prefilled syringe. The aim of this study was to evaluate the efficacy and safety of this new long-acting formulation in a large population of acromegalic patients previously responsive to lanreotide 30 mg, im (sustained release microparticle formulation). Lanreotide Autogel was administered by deep sc injection every 28 d to 107 patients (54 males and 53 females; mean age, 54 ± 1.2 yr). All patients had been treated with lanreotide (30 mg) for at least 3 months before study entry and had a mean GH level less than 10 ng/ml after at least 4 subsequent im injections every 14 d (48%), 10 d (32%), or 7 d (20%). Treatment was switched from lanreotide 30 mg injected every 14, 10, or 7 d to 60, 90, or 120 mg lanreotide Autogel, respectively, every 28 d. After three fixed dose injections of lanreotide Autogel, mean lanreotide levels were similar to those obtained at steady state with lanreotide 30 mg. During lanreotide Autogel treatment, the control of acromegalic symptoms was comparable with that previously achieved during lanreotide 30 mg treatment. After 3 injections of lanreotide Autogel, mean GH (2.87 ± 0.22 ng/ml) and IGF-I (317 ± 15 ng/ml) values were comparable with those recorded at the end of lanreotide 30 mg treatment (GH, 2.82 ± 0.19 ng/ml; IGF-I, 323 ± 16 ng/ml). GH levels below 2.5 ng/ml and age-/sex-normalized IGF-I were achieved in 33% and 39% of patients during lanreotide 30 mg and lanreotide Autogel treatment, respectively. Diarrhea, abdominal pain, and nausea were reported by 38%, 22%, and 18% of patients during lanreotide 30 mg treatment and by 29%, 17%, and 9% of patients, respectively, during lanreotide Autogel treatment. In conclusion, this clinical study shows that lanreotide Autogel is at least as efficacious and well tolerated as lanreotide 30 mg. This new long-acting lanreotide formulation, lanreotide Autogel, which is administered from a small volume, prefilled syringe by deep sc injection, is therefore likely to improve the acceptability of medical treatment for patients requiring long-term somatostatin analog therapy.

Original languageEnglish
Pages (from-to)99-104
Number of pages6
JournalJournal of Clinical Endocrinology and Metabolism
Volume87
Issue number1
DOIs
Publication statusPublished - 2002

Fingerprint

Acromegaly
Injections
lanreotide
Insulin-Like Growth Factor I
Therapeutics
Syringes

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. / Caron, Ph; Beckers, A.; Cullen, D. R.; Góth, M.; Gutt, B.; Laurberg, P.; Pico, A. M.; Valimaki, M.; Zgliczynski, W.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 87, No. 1, 2002, p. 99-104.

Research output: Contribution to journalArticle

Caron, P, Beckers, A, Cullen, DR, Góth, M, Gutt, B, Laurberg, P, Pico, AM, Valimaki, M & Zgliczynski, W 2002, 'Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly', Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 1, pp. 99-104. https://doi.org/10.1210/jc.87.1.99
Caron, Ph ; Beckers, A. ; Cullen, D. R. ; Góth, M. ; Gutt, B. ; Laurberg, P. ; Pico, A. M. ; Valimaki, M. ; Zgliczynski, W. / Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. In: Journal of Clinical Endocrinology and Metabolism. 2002 ; Vol. 87, No. 1. pp. 99-104.
@article{f8266a78b9ed482a8be10bfe20cf0a37,
title = "Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly",
abstract = "Lanreotide Autogel is a new long-acting aqueous preparation of lanreotide for the treatment of acromegaly and is administered by deep sc injection from a small volume, prefilled syringe. The aim of this study was to evaluate the efficacy and safety of this new long-acting formulation in a large population of acromegalic patients previously responsive to lanreotide 30 mg, im (sustained release microparticle formulation). Lanreotide Autogel was administered by deep sc injection every 28 d to 107 patients (54 males and 53 females; mean age, 54 ± 1.2 yr). All patients had been treated with lanreotide (30 mg) for at least 3 months before study entry and had a mean GH level less than 10 ng/ml after at least 4 subsequent im injections every 14 d (48{\%}), 10 d (32{\%}), or 7 d (20{\%}). Treatment was switched from lanreotide 30 mg injected every 14, 10, or 7 d to 60, 90, or 120 mg lanreotide Autogel, respectively, every 28 d. After three fixed dose injections of lanreotide Autogel, mean lanreotide levels were similar to those obtained at steady state with lanreotide 30 mg. During lanreotide Autogel treatment, the control of acromegalic symptoms was comparable with that previously achieved during lanreotide 30 mg treatment. After 3 injections of lanreotide Autogel, mean GH (2.87 ± 0.22 ng/ml) and IGF-I (317 ± 15 ng/ml) values were comparable with those recorded at the end of lanreotide 30 mg treatment (GH, 2.82 ± 0.19 ng/ml; IGF-I, 323 ± 16 ng/ml). GH levels below 2.5 ng/ml and age-/sex-normalized IGF-I were achieved in 33{\%} and 39{\%} of patients during lanreotide 30 mg and lanreotide Autogel treatment, respectively. Diarrhea, abdominal pain, and nausea were reported by 38{\%}, 22{\%}, and 18{\%} of patients during lanreotide 30 mg treatment and by 29{\%}, 17{\%}, and 9{\%} of patients, respectively, during lanreotide Autogel treatment. In conclusion, this clinical study shows that lanreotide Autogel is at least as efficacious and well tolerated as lanreotide 30 mg. This new long-acting lanreotide formulation, lanreotide Autogel, which is administered from a small volume, prefilled syringe by deep sc injection, is therefore likely to improve the acceptability of medical treatment for patients requiring long-term somatostatin analog therapy.",
author = "Ph Caron and A. Beckers and Cullen, {D. R.} and M. G{\'o}th and B. Gutt and P. Laurberg and Pico, {A. M.} and M. Valimaki and W. Zgliczynski",
year = "2002",
doi = "10.1210/jc.87.1.99",
language = "English",
volume = "87",
pages = "99--104",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "1",

}

TY - JOUR

T1 - Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly

AU - Caron, Ph

AU - Beckers, A.

AU - Cullen, D. R.

AU - Góth, M.

AU - Gutt, B.

AU - Laurberg, P.

AU - Pico, A. M.

AU - Valimaki, M.

AU - Zgliczynski, W.

PY - 2002

Y1 - 2002

N2 - Lanreotide Autogel is a new long-acting aqueous preparation of lanreotide for the treatment of acromegaly and is administered by deep sc injection from a small volume, prefilled syringe. The aim of this study was to evaluate the efficacy and safety of this new long-acting formulation in a large population of acromegalic patients previously responsive to lanreotide 30 mg, im (sustained release microparticle formulation). Lanreotide Autogel was administered by deep sc injection every 28 d to 107 patients (54 males and 53 females; mean age, 54 ± 1.2 yr). All patients had been treated with lanreotide (30 mg) for at least 3 months before study entry and had a mean GH level less than 10 ng/ml after at least 4 subsequent im injections every 14 d (48%), 10 d (32%), or 7 d (20%). Treatment was switched from lanreotide 30 mg injected every 14, 10, or 7 d to 60, 90, or 120 mg lanreotide Autogel, respectively, every 28 d. After three fixed dose injections of lanreotide Autogel, mean lanreotide levels were similar to those obtained at steady state with lanreotide 30 mg. During lanreotide Autogel treatment, the control of acromegalic symptoms was comparable with that previously achieved during lanreotide 30 mg treatment. After 3 injections of lanreotide Autogel, mean GH (2.87 ± 0.22 ng/ml) and IGF-I (317 ± 15 ng/ml) values were comparable with those recorded at the end of lanreotide 30 mg treatment (GH, 2.82 ± 0.19 ng/ml; IGF-I, 323 ± 16 ng/ml). GH levels below 2.5 ng/ml and age-/sex-normalized IGF-I were achieved in 33% and 39% of patients during lanreotide 30 mg and lanreotide Autogel treatment, respectively. Diarrhea, abdominal pain, and nausea were reported by 38%, 22%, and 18% of patients during lanreotide 30 mg treatment and by 29%, 17%, and 9% of patients, respectively, during lanreotide Autogel treatment. In conclusion, this clinical study shows that lanreotide Autogel is at least as efficacious and well tolerated as lanreotide 30 mg. This new long-acting lanreotide formulation, lanreotide Autogel, which is administered from a small volume, prefilled syringe by deep sc injection, is therefore likely to improve the acceptability of medical treatment for patients requiring long-term somatostatin analog therapy.

AB - Lanreotide Autogel is a new long-acting aqueous preparation of lanreotide for the treatment of acromegaly and is administered by deep sc injection from a small volume, prefilled syringe. The aim of this study was to evaluate the efficacy and safety of this new long-acting formulation in a large population of acromegalic patients previously responsive to lanreotide 30 mg, im (sustained release microparticle formulation). Lanreotide Autogel was administered by deep sc injection every 28 d to 107 patients (54 males and 53 females; mean age, 54 ± 1.2 yr). All patients had been treated with lanreotide (30 mg) for at least 3 months before study entry and had a mean GH level less than 10 ng/ml after at least 4 subsequent im injections every 14 d (48%), 10 d (32%), or 7 d (20%). Treatment was switched from lanreotide 30 mg injected every 14, 10, or 7 d to 60, 90, or 120 mg lanreotide Autogel, respectively, every 28 d. After three fixed dose injections of lanreotide Autogel, mean lanreotide levels were similar to those obtained at steady state with lanreotide 30 mg. During lanreotide Autogel treatment, the control of acromegalic symptoms was comparable with that previously achieved during lanreotide 30 mg treatment. After 3 injections of lanreotide Autogel, mean GH (2.87 ± 0.22 ng/ml) and IGF-I (317 ± 15 ng/ml) values were comparable with those recorded at the end of lanreotide 30 mg treatment (GH, 2.82 ± 0.19 ng/ml; IGF-I, 323 ± 16 ng/ml). GH levels below 2.5 ng/ml and age-/sex-normalized IGF-I were achieved in 33% and 39% of patients during lanreotide 30 mg and lanreotide Autogel treatment, respectively. Diarrhea, abdominal pain, and nausea were reported by 38%, 22%, and 18% of patients during lanreotide 30 mg treatment and by 29%, 17%, and 9% of patients, respectively, during lanreotide Autogel treatment. In conclusion, this clinical study shows that lanreotide Autogel is at least as efficacious and well tolerated as lanreotide 30 mg. This new long-acting lanreotide formulation, lanreotide Autogel, which is administered from a small volume, prefilled syringe by deep sc injection, is therefore likely to improve the acceptability of medical treatment for patients requiring long-term somatostatin analog therapy.

UR - http://www.scopus.com/inward/record.url?scp=0036148030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036148030&partnerID=8YFLogxK

U2 - 10.1210/jc.87.1.99

DO - 10.1210/jc.87.1.99

M3 - Article

VL - 87

SP - 99

EP - 104

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 1

ER -